P2Y12 Platelet Function Test | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
|||||||||
MiChart Code: Plavix Platelet Function Test
|
|||||||||
Soft Order Code: P2Y12
|
|||||||||
Synonyms:
|
|||||||||
Container: Blue top tube, 3.2% sodium citrate
|
|||||||||
Normal Volume: Full 2.7mL tube preferred, full 1.8mL tube is acceptable
|
|||||||||
Minimum Volume: Full 2.7mL tube preferred, full 1.8mL tube is acceptable
|
|||||||||
Special Handling: DO NOT SEND THROUGH PNEUMATIC TUBE SYSTEM.
|
|||||||||
Offsite Collection: Collect specimen in a 2.7 mL blue top (citrate 3.2%) tube using a 21 gauge or larger needle. Mix by inversion. Do not centrifuge. Whole blood specimen should arrive at lab within 3 hours of collection; transport at room temperature. Collection of the blood through lines that have been previously flushed with heparin should be avoided. If the blood must be drawn through a VAD (vascular access device), the line should be flushed with 5 mL of saline and the first 5 mL of blood or six dead space volumes of the VAD discarded.
|
|||||||||
Onsite Collection (Michigan Medicine Hospitals Only): DO NOT SEND THROUGH PNEUMATIC TUBE SYSTEM. Collect specimen in a blue top (citrate 3.2%) tube using a 21 gauge or larger needle. Mix by inversion. Send specimen to lab within 3 hours of collection. Collection of the blood through lines that have been previously flushed with heparin should be avoided. If the blood must be drawn through a VAD (vascular access device), the line should be flushed with 5 mL of saline and the first 5 mL of blood or six dead space volumes of the VAD discarded.
|
|||||||||
Days Set Up: Daily, 24 hours
|
|||||||||
Analytic Time: 1 hour
|
|||||||||
Reference Range: *Reference ranges may change over time. Please refer to the original patient report when evaluating results.
180 - 376 PRU. Values less than 180 PRU may be evidence of a P2Y12 inhibitor effect.
|
|||||||||
Test Usage: To determine the degree of platelet inhibition from the use of P2Y12 inhibition drug therapies known as thienopyridines. These include Clopidogrel (Plavix), Prasugrel, Ticlopidine (Ticlid), and Ticagrelor.
|
|||||||||
Contraindications: Patients who have been administered glycoprotein IIb/IIIa inhibitors tirofiban (Aggrastat) or eptifibatide (Integrilin) within the last 2 days or abciximab (ReoPro) within the last 2 weeks should not be tested.
|
|||||||||
Test Limitations:
|
|||||||||
Test Methodology: Automated platelet induced aggregation.
|
|||||||||
Additional Information: Surgical Screen: Patients administered anti-platelet therapies are at risk of increased bleeding during operations. It is recommended that patients on P2Y12 inhibitors undergoing surgery or invasive procedures be tested preoperatively. Test results may aid in decisions to initiate or delay surgery, and to make preparations for additional blood product use if surgery cannot be postponed. Therapeutic Response: Variability in patient response to anti-platelet drugs is common. It is recommended that patients on P2Y12 inhibitors be tested to determine if the drug has produced the expected antiplatelet effect.
|
|||||||||
CPT Code: 85576
Fee Code:35500
Rejection Criteria:Specimens will be rejected if not properly filled, clotted, grossly hemolyzed, or contaminated with heparin, or sent through the pneumatic tube system.
|
|||||||||
Test ID: 1119
|